Changes in the intestinal microbiota of patients with Parkinson’s disease and their clinical significance

To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls. 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical pharmacology and therapeutics Vol. 61; no. 2; pp. 48 - 58
Main Authors Zhang, Li-Na, Yuan, Wen-Ling, Ye, Ming, Yin, Liang, Wang, Shi-Jie
Format Journal Article
LanguageEnglish
Published Germany Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 01.02.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls. 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups. The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of and was increased in the PD group (p < 0.01), while the relative abundance of was significantly lower (p < 0.01). The relative abundance of , , and in the PD group was significantly higher than in the control group (p < 0.05). Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.
AbstractList To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.OBJECTIVETo investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.MATERIALS AND METHODS20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).RESULTSThe operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.CONCLUSIONCompared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.
To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls. 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups. The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of and was increased in the PD group (p < 0.01), while the relative abundance of was significantly lower (p < 0.01). The relative abundance of , , and in the PD group was significantly higher than in the control group (p < 0.05). Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.
Objective: To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson’s disease (PD) in comparison to those in healthy controls.Materials and methods: 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.Results: The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).Conclusion: Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.
Author Yin, Liang
Zhang, Li-Na
Yuan, Wen-Ling
Wang, Shi-Jie
Ye, Ming
Author_xml – sequence: 1
  givenname: Li-Na
  surname: Zhang
  fullname: Zhang, Li-Na
– sequence: 2
  givenname: Wen-Ling
  surname: Yuan
  fullname: Yuan, Wen-Ling
– sequence: 3
  givenname: Ming
  surname: Ye
  fullname: Ye, Ming
– sequence: 4
  givenname: Liang
  surname: Yin
  fullname: Yin, Liang
– sequence: 5
  givenname: Shi-Jie
  surname: Wang
  fullname: Wang, Shi-Jie
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36420886$$D View this record in MEDLINE/PubMed
BookMark eNplkT1OJDEQhR2Alp9diRMgSyQkA_7tbodoxAISEgS7ccvtrmYKeuzB9giRcY3NOAtH4SR4BAMSG1UFXz3Ve2-HbPjggZA9zo604up4ei2YEo3eINvMqGrCTaW3yE5Kt4wJrWvzg2zJSgnWNNU2Gacz628gUfQ0z6CMDCmjtyOdo4uhw5AtDcPL88JmBJ8TfcA8o9c23qFPwb8-_Uu0xwQ2AbW-X6lgpG5Ej66oJLzxOJTVO_hJNgc7Jvj1MXfJ39-nf6bnk8urs4vpyeXESc7zBDQI5cAKAKGN7OsKlNKdqTsmOwFDz3s9COuscJr3zEKlmtpJWXVSGWiU3CWH77qLGO6XxU87x-RgHK2HsEytqKWpFWdSFvTgG3oblrHYX1GVUYUzplD7H9Sym0PfLiLObXxs1zkW4OgdKJGlFGFoHeYSWPA5WhxbztpVOe26nK8XPw_Wmv-hbwzXkjs
CitedBy_id crossref_primary_10_3390_biomedicines11102658
ContentType Journal Article
Copyright Copyright Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 2023
Copyright_xml – notice: Copyright Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.5414/CP204285
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EndPage 58
ExternalDocumentID 36420886
10_5414_CP204285
Genre Journal Article
GroupedDBID ---
36B
5GY
7X7
88E
8FI
8FJ
AAYXX
ABJNI
ABUWG
ACGFO
ACGFS
ADBBV
AENEX
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
DLWAR
EBS
EJD
EMB
F5P
FYUFA
HMCUK
M1P
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
SJN
UKHRP
VDS
~4P
.GJ
53G
AFFNX
CGR
CUY
CVF
ECM
EIF
EMOBN
MK0
NPM
SV3
ZGI
ZXP
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c311t-e5e24cea2ee2593d76e445b97b03b2efd1d5f2aca2c51d0ae6487c336b349e843
IEDL.DBID 7X7
ISSN 0946-1965
IngestDate Fri Jul 11 00:02:53 EDT 2025
Fri Jul 25 04:12:01 EDT 2025
Thu Apr 03 07:02:38 EDT 2025
Tue Jul 01 01:26:44 EDT 2025
Thu Apr 24 23:10:24 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c311t-e5e24cea2ee2593d76e445b97b03b2efd1d5f2aca2c51d0ae6487c336b349e843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 36420886
PQID 2769497499
PQPubID 2044854
PageCount 11
ParticipantIDs proquest_miscellaneous_2739741033
proquest_journals_2769497499
pubmed_primary_36420886
crossref_citationtrail_10_5414_CP204285
crossref_primary_10_5414_CP204285
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-01
2023-Feb
20230201
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Munich
PublicationTitle International journal of clinical pharmacology and therapeutics
PublicationTitleAlternate Int J Clin Pharmacol Ther
PublicationYear 2023
Publisher Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Publisher_xml – name: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
SSID ssj0025579
Score 2.3572285
Snippet To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in...
Objective: To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson’s disease (PD) in comparison...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 48
SubjectTerms Biomarkers
Clinical Relevance
Clinical significance
Feces - microbiology
Gastrointestinal Microbiome
Humans
Microbiota
Parkinson Disease - diagnosis
Parkinson's disease
Title Changes in the intestinal microbiota of patients with Parkinson’s disease and their clinical significance
URI https://www.ncbi.nlm.nih.gov/pubmed/36420886
https://www.proquest.com/docview/2769497499
https://www.proquest.com/docview/2739741033
Volume 61
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA4-Ll7Et-uLEUQvFrdJk7YnUVFEUBZR2FtJkxRE7a52PXjzb_j3_CXOtOkugnpuSKAzk3zz-oaxPaULLnWhgkRQtCp1YZBYV6DFaxkjhEBQQr3D1zfq8j666su-D7hVvqyyvRPri9oODMXIj3is0gjBb5oeD18CmhpF2VU_QmOazRJ1GWl13J84XFJ6rr1IBcSc15DP0uDro7MeJ29B_nyO_sCY9VtzscDmPUiEk0aqi2zKlUtsv9ewTL8fwt2kaao6hH3oTfin35fZY9MxUMFDCQjvgBgh0JBpx-eHhndppGFQgOdUrYCCsUD9z3Ur2NfHZwU-cQO6tFAnE6DtoQQq-aACI9KXFXZ_cX53dhn4mQqBEWE4Cpx0PDJOc-fQ8RE2Vi6KZJ7GeVfk3BU2tLLg2mhuZGi72in0aIwQKhcoyCQSq2ymHJRunYGJE1s4k3Oh6IlD3CCtlXHcTdGw0Q_rsIP212bGE47T3IunDB0PEkLWCqHDdscrhw3Jxi9rtlrpZN7MqmyiFLjF-DMaCGU9dOkGb7QGIVcUdoXosLVGquNDhKLqgkRt_L_5JpujKfNNsfYWmxm9vrltxCKjfKdWuB02e3p-07v9BkJ24HI
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VcoAL4p-FAoME5dKoiR07yQEhVKi29Ed72Ep7C47tSBWQLWQrtDdeg5fgoXgSZuJkV0jAredYEyUznvnGnvkG4Lk2tVCm1lEu-bSq8EmUO1_TjjcqIwhBoIR7h49P9Pg0fT9Tsw34OfTCcFnl4BM7R-3mls_Id0Wmi5TAb1G8Pv8S8dQovl0dRmgEszj0y2-UsrWvDt6Sfl8Isf9uujeO-qkCkZVJsoi88iK13gjvCfpLl2mfpqoqsiqWlfC1S5yqhbFGWJW42HhNmN5KqStJn5KnkuRegasUeGNO9rLZOsFTquf2S3XETH2B7JYHbe_uTQRnJ-rP8PcPTNvFtv2bcKMHpfgmWNEt2PDNbdieBFbr5Q5O101a7Q5u42TNd728Ax9Dh0KLZw0SnERmoCDHwRI_nwWep4XBeY09h2uLfPiL3G_dtZ79-v6jxf6iCE3jsLu8wKFnE7nEhAua2D7vwuml_O17sNnMG_8A0Ga5q72thNQcUgmnKOdUlsUFORLK-0bwcvi1pe0JznnOxqeSEh1WQjkoYQTPVivPA6nHX9ZsDdop-23dlmsjJBGrx7Qh-ZbFNH5-wWsI4qVJLOUI7getrl4iNVcz5Prh_4U_hWvj6fFReXRwcvgIrvOE-1AovgWbi68X_jHhoEX1pDM-hA-Xbe2_ASQSHJA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+the+intestinal+microbiota+of+patients+with+Parkinson%27s+disease+and+their+clinical+significance&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Zhang%2C+Li-Na&rft.au=Yuan%2C+Wen-Ling&rft.au=Ye%2C+Ming&rft.au=Yin%2C+Liang&rft.date=2023-02-01&rft.issn=0946-1965&rft.volume=61&rft.issue=2&rft.spage=48&rft_id=info:doi/10.5414%2FCP204285&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon